Moreover, our study is supported by another group from The Scripps Research Institute, which showed that CCR5 expression in both CD4+ and CD8+ T cells was necessary to activate cancer immune response that might have implications for cancer treatment in patients with CCR5 deficiency. The gene discussed is CCR5; the disease is cancer.